Welcome to our dedicated page for Incannex Healthcare news (Ticker: IXHL), a resource for investors and traders seeking the latest updates and insights on Incannex Healthcare stock.
Incannex Healthcare Inc. reports company developments tied to its clinical-stage combination therapy pipeline, Nasdaq listing status and capital actions. Recurring updates describe IHL-42X, its oral fixed-dose combination program for obstructive sleep apnea, including clinical development strategy, sleep-medicine research partnerships and FDA Fast Track Designation.
News also covers PSX-001, the company’s oral synthetic botanical research compound formulation for generalized anxiety disorder, along with balance-sheet commentary, share repurchase activity, reverse stock split disclosures and Nasdaq minimum bid price compliance. The company’s communications generally center on clinical progress, regulatory context, financing capacity and public-company capital structure.
Incannex Healthcare (Nasdaq: IXHL) has officially commenced its DReAMzz clinical study of IHL-42X for obstructive sleep apnea (OSA). The crossover dose-optimization trial uses 14 clinical sites, with drug manufacturing, permits, and global distribution logistics in place.
The study aims to refine dosing and de-risk a planned Phase III program, building on positive Phase II RePOSA results and supported by FDA Fast Track designation for IHL-42X in OSA.
Incannex Healthcare (Nasdaq: IXHL) won the MedTech Breakthrough “Best New Technology Solution for Drug Development” award for its lead candidate IHL-42X, an oral combination therapy for obstructive sleep apnea (OSA).
According to Incannex, Phase 2 data showed statistically significant AHI reductions and improved oxygenation, sleep quality, and fatigue.
Incannex Healthcare (Nasdaq: IXHL) says its oral synthetic psilocybin program PSX-001 for Generalized Anxiety Disorder aligns with the White House Executive Order dated April 18, 2026. The company cites Phase 2 results showing a 12.8-point HAM-A reduction vs 3.6 placebo, 44% response and 27% remission in 73 patients.
Incannex reports no serious adverse events, an active U.S. IND, and over $70 million cash with no debt. The Executive Order could speed regulatory pathways but requires Phase 3 success for DEA rescheduling.
Incannex Healthcare (Nasdaq: IXHL) has reactivated its previously approved share repurchase program and executed repurchases over the past two trading days. The Board cited a belief that market valuation understates the company’s balance sheet, clinical progress, and future potential.
The company reported approximately $75 million in cash and no debt after recent financing, and stated that about $18.5 million remained available for repurchases as of December 31, 2025. The program is discretionary and may be modified, suspended, or discontinued.
Incannex Healthcare (Nasdaq: IXHL) has partnered with the AASM Foundation to sponsor a 2026 Focused Projects Grant for junior investigators in sleep apnea research and joined the Foundation’s Corporate Recognition Program.
Incannex continues advancing IHL-42X — an oral dronabinol/acetazolamide combination — after positive Phase 2 results, FDA Fast Track designation, and initiation of the DReAMzz Phase 2 dose-optimisation study with patient dosing expected within months toward a planned Phase 3 pathway.
Incannex (Nasdaq: IXHL) reported approximately $75 million in cash and no debt after a recent financing, while market capitalization is about $46 million, producing a negative enterprise value. Proceeds will fund the DReAMzz Phase 2 dose-optimization study for IHL-42X; PSX-001 development continues with an open IND.
The company expects to begin dosing in DReAMzz in the coming months and retains a board-approved share buyback program.
Incannex Healthcare (Nasdaq: IXHL) regained compliance with Nasdaq Listing Rule 5550(a)(2) after its common stock maintained a closing bid of $1.00 or greater for eleven consecutive business days from February 27 through March 13, 2026. Nasdaq has confirmed the company satisfied continued listing requirements and the matter is closed.
The company reported approximately $75 million in cash, no debt, and cited ongoing clinical development of IHL-42X for obstructive sleep apnea (statistically significant Phase 2) and PSX-001 for generalized anxiety disorder (positive outcomes).
Incannex Healthcare (Nasdaq: IXHL) priced a registered direct offering to raise approximately $10.0 million by issuing 2,000,000 common shares and accompanying warrants at a combined purchase price of $5.00 per share, expected to close on or about March 13, 2026.
If all warrants are exercised for cash at an exercise price of $6.50, Incannex could receive up to an additional $13.0 million, bringing total potential gross proceeds to about $23.0 million. Proceeds are expected to fund completion of the DReAMzz Phase 2 study for IHL-42X and for working capital; the company has terminated its ATM facility.
Incannex (Nasdaq: IXHL) announced an enhanced development pathway for oral OSA candidate IHL-42X after statistically significant Phase 2 RePOSA results and receipt of FDA Fast Track designation. The company will run a Phase 2 crossover dose-optimization study (DReAMzz) testing dronabinol/acetazolamide ratios, then pursue a streamlined Phase 3 master-protocol program to strengthen efficacy data and improve capital efficiency. Incannex expects to begin dosing in DReAMzz in the coming months.
Incannex (Nasdaq: IXHL) approved a 1-for-30 reverse stock split to be effective 4:01 p.m. ET on February 26, 2026 and will trade on a split-adjusted basis on February 27, 2026.
The reverse split will convert each 30 pre-split shares into one post-split share, reducing outstanding shares from approximately 358,329,368 to about 11,944,313. No fractional-share cash payments will be made; fractional interests will be rounded up. Proportional adjustments will apply to equity awards and the stock incentive plan.